<DOC>
	<DOCNO>NCT00598663</DOCNO>
	<brief_summary>The primary objective study evaluate whether patient Type 1 diabetes mellitus sub-optimal glycemic control achieve good glycemic control use Medtronic MiniMed Paradigm® REAL-Time Pump System continuous glucose monitoring versus Medtronic MiniMed Paradigm® REAL-Time Pump alone Self Monitoring Blood Glucose ( SMBG ) .Our null hypothesis 0 % reduction HbA1c baseline compare control group , 6 month treatment .</brief_summary>
	<brief_title>SWITCH - Sensing With Insulin Pump Therapy Control HbA1c</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 1 diabetes mellitus diagnose least 12 month prior signature inform consent , Suboptimal glycemic control ( 7.5 % &lt; HbA1c &lt; 9.5 % ) . Patient treat continuous subcutaneous insulin infusion ( CSII ) least 6 month prior signature inform consent . Patient treat within practice investigator 's center least 6 month prior signature inform consent . Patient preliminary experience sensor function Paradigm REALTime Guardian® REALTime 4 month prior signature inform consent . Existing pregnancy intention conceive ( assessed investigator ) . Hearing vision impairment glucose display alarm recognize . Three incident last 12 month severe hypoglycaemia document Blood Glucose 50mg/dL ( possible ) , result unconsciousness , hospitalisation third party assistance , recovery follow treatment glucose glucagon similar . History hypoglycemic unawareness assess investigator . Alcohol drug abuse , nicotine . Documented cutaneous allergy disease ( allergy sensor component sensor , psoriasis , staphylococcus , exanthema etc. ) . Any documented concomitant chronic disease know affect diabetes control ( e.g . alter renal function , active cancer undergo treatment , Crohn 's disease , ulcerative colitis , Mb Addison disease ) concomitant pharmacological treatment might modify glycemic value ( e.g chronic corticosteroid therapy ) , eat disorder morbid obesity ( define adult : Body Mass Index &gt; 35 child Body Mass Index &gt; 2 standard deviation . age ) assess investigator . Any medical , social psychological condition , investigator 's opinion , make patient unable comply study protocol study procedure . For pediatric subject : reliable support person . Plans travel extend period ( 3+ week ) device supply replaced and/or medical support limit ( eg . exotic country , remote place ) . Participation another clinical study , ongoing complete less 3 month prior signature Patient Informed Consent .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Type 1 diabetes</keyword>
</DOC>